x
Filter:
Filters applied
- JTO: Editors Choice
- CrizotinibRemove Crizotinib filter
- HypersensitivityRemove Hypersensitivity filter
Editors Choice
1 Results
- Brief ReportsOpen Archive
Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib
Journal of Thoracic OncologyVol. 9Issue 11p1726–1728Published in issue: November, 2014- Mark M. Awad
- Timothy P. Lax
- Benjamin R. Slawski
- Alice T. Shaw
Cited in Scopus: 20The tyrosine kinase inhibitor crizotinib is an effective therapy for patients with cancers harboring rearrangements of the anaplastic lymphoma kinase (ALK) gene. Here, we describe two patients with advanced ALK-positive lung cancer who developed hypersensitivity to crizotinib, requiring temporary discontinuation of the drug. Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity.
